Biospectal SA, a remote patient monitoring and biosensing software company, closed a $4.3 million seed funding round led by digital health investor, SeedLink, with additional funding from LabCorp, Athensmed, Swiss based Privilege Ventures and other European and US investors. Biospectal will leverage the new funds to scale its OptiBP™ smartphone blood pressure monitoring application and data platform technology worldwide. Biospectal OptiBP for Android launched in public beta in January 2021. Biospectal OptiBP for iOS is currently in alpha and is planned for public beta launch in the second half of 2021. Read more.
Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink
